ADTX vs BMY · rev $3.2K vs P/E 17, rev $24.46B
Aditxt Inc. (ADTX) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
Aditxt Inc. (ADTX) is a biotechnology company listed on NASDAQ.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Latest reported ADTX revenue for 2025-12-31 was $3.2K. Net income was -$43.1M. Revenue was down 97.6% from 2024-12-31 to 2025-12-31. ADTX currently screens at market cap $3.6K.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
ADTX currently screens at market cap $3.6K. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the ADTX and BMY stock pages for the full models.
Not investment advice.